Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | CDC42 | P60953 | 1/20 | 0.38 |
| ▸ | RAC1 | P63000 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL1023377 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA4P2RY14HSD17B1HSD17B2 | |
| SCHEMBL1022337 | 0.89 | CHRNB2 (0.52) | CHRNB2CHRNA4P2RY14HSD17B1HSD17B2 | |
| SCHEMBL1022339 | 0.89 | CHRNB2 (0.52) | CHRNB2CHRNA4P2RY14HSD17B1HSD17B2 | |
| Cadaverine Tartrate SCHEMBL1023809 | 0.87 | P2RY14 (0.45) | CHRNB2CHRNA4P2RY14 | |
| Cadaverine Tartrate SCHEMBL1023808 | 0.87 | P2RY14 (0.45) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL7805901 | 0.77 | CHRNB2 (0.54) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL1023383 | 0.74 | CHRNB2 (0.48) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL1023384 | 0.74 | CHRNB2 (0.48) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL1023489 | 0.74 | CHRNB2 (0.54) | CHRNB2CHRNA4P2RY14 | |
| Hydrochloric Acid SCHEMBL1072684 | 0.73 | CHRNB2 (0.47) | CHRNB2CHRNA4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272847-A1 | Enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors | NeuroSearch A/S (DK) | 2011-01-12 | — | — | EP | disclosed |
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-1869033-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108789-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | CHRNB2 90/4885CHRNA4 129/4885P2RY14 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.